Ilorasertib hydrochloride

Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC 50 s of116, 5, 1 nM for aurora A , aurora B , aurora C , respectively. Ilorasertib hydrochloride also is a potent VEGF , PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In Vitro Ilorasertib hydrochloride (0, 3, 10, 30 nM; 24 h) induces a concentration-dependent increase in the extent and number of H1299, H460 cells. Ilorasertib hydrochloride (1-1000 nM) shows antiproliferative activity. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: H1299, H460 cells Concentration: 0, 3, 10, 30 nM Incubation Time: 24 h Result: Induced a concentration-dependent increase in the extent and number of cells exhibiting polyploidy with EC 50 S of 5, 10 nM for H1299, H460 cells, respectively. Cell Proliferation AssayCell Line: MV-4-11, SEM, K562, HCT-15, SW620, H1299, H460 cells Concentration: 1-1000 nM Incubation Time: Result: Showed antiproliferative activity with IC 50 s of 0.3, 1, 103, 6, 6, 2, 2 nM for MV-4-11, SEM, K562, HCT-15, SW620, H1299, H460 cells, respectively. In Vivo Ilorasertib hydrochloride (6.25, 12.5, 25 mg/kg; p.o.) shows anti-tumor activity in MV-4-11 tumor-bearing SCID mice with TGI of 80%, 86%, 94% at 6.25, 12.5, 25 mg/kg, respectively . Ilorasertib hydrochloride (6.25, 12.5, 25 mg/kg; p.o.) shows anti-tumor activity in SKM-1 tumor-bearing SCID mice with TGI of 38%, 59%, 80% at 6.25, 12.5, 25 mg/kg, respectively . Ilorasertib hydrochloride (0, 3.75, 7.5, 15 mg/kg; i.p.) inhibits the histone H3 phosphorylation at 4-8 h in blood-borne tumor cells. Ilorasertib hydrochloride (0.2 mg/kg; i.v.) shows anti-VEGF activity in mouse. Ilorasertib hydrochloride (20 mg/kg; p.o.;once weekly for 3 weeks) shows anti-tumor activity in mouse. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female SCID/beige miceDosage: 25 mg/kg Administration: Subcutaneous minipump; 24 h Result: Inhibited the histone H3 phosphorylation and the tumor drug concentration associated with 50% inhibition of histone H3 phosphorylation. Animal Model: 22-26 g, female NOD/SCID mice (xenograft model of multiple myeloma (KMS11))Dosage: 20 mg/kg Administration: P.o.; once weekly for 3 weeks Result: Inhibited the tumor growth in mouse. Form:Solid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet